[{"orgOrder":0,"company":"Huadong Medicine","sponsor":"Ashvattha Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Dendrimer N-acetyl-cysteine","moa":"IKK beta","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Huadong Medicine","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"Huadong Medicine \/ Huadong Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Huadong Medicine \/ Huadong Medicine"},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"CARsgen Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Zevorcabtagene Autoleucel","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Huadong Medicine","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Infusion","sponsorNew":"Huadong Medicine \/ Huadong Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Huadong Medicine \/ Huadong Medicine"},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Roflumilast","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Huadong Medicine","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.089999999999999997,"dosageForm":"Cream","sponsorNew":"Huadong Medicine \/ Huadong Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Huadong Medicine \/ Huadong Medicine"},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"HDM1002","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Huadong Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Huadong Medicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Huadong Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"SynerK PharmaTech","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"SNK-2726","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"Huadong Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Huadong Medicine \/ SynerK PharmaTech","highestDevelopmentStatusID":"4","companyTruncated":"Huadong Medicine \/ SynerK PharmaTech"}]

Find Clinical Drug Pipeline Developments & Deals by Huadong Medicine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AAM
                          Not Confirmed
                          AAM
                          Not Confirmed

                          Details : Through the collaboration, the two parties will jointly develop the small nucleic acid (siRNA) drug SNK-2726, which targets angiotensinogen (AGT) for the treatment of hypertension.

                          Product Name : Undisclosed

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          December 30, 2024

                          Lead Product(s) : SNK-2726

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Preclinical

                          Sponsor : SynerK PharmaTech

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          AAM
                          Not Confirmed
                          AAM
                          Not Confirmed

                          Details : HDM1002 is an innovative potent small molecule drug, highly selective full agonist of the GLP-1 receptor. It is being developed for Type 2 Diabetes Mellitus.

                          Product Name : HDM1002

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 26, 2024

                          Lead Product(s) : HDM1002

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          AAM
                          Not Confirmed
                          AAM
                          Not Confirmed

                          Details : Under the collaboration, Huadong will receive license for both the cream and foam formulations of topical Zoryve (roflumilast), a next generation PDE4 inhibitor, for multiple dermatological conditions including plaque psoriasis, seborrheic dermatitis, an...

                          Product Name : Zoryve

                          Product Type : Small molecule

                          Upfront Cash : $30.0 million

                          August 10, 2023

                          Lead Product(s) : Roflumilast

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Recipient : Arcutis Biotherapeutics

                          Deal Size : $94.2 million

                          Deal Type : Collaboration

                          blank

                          04

                          AAM
                          Not Confirmed
                          AAM
                          Not Confirmed

                          Details : Under the terms of the exclusive licensing agreement, Huadong will advance research and development costs for Ashvattha’s hydroxyl dendrimer clinical candidates, OP-101, D-4517.2 and OP-801, and for additional preclinical candidates.

                          Product Name : OP-101

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          April 27, 2022

                          Lead Product(s) : Dendrimer N-acetyl-cysteine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Recipient : Ashvattha Therapeutics

                          Deal Size : $45.0 million

                          Deal Type : Licensing Agreement

                          blank

                          05

                          AAM
                          Not Confirmed
                          AAM
                          Not Confirmed

                          Details : CT053 (zevorcabtagene autoleucel), is a fully human, autologous BCMA CAR T-cell product candidate for the treatment of relapsed/refractory multiple myeloma (R/R MM).

                          Product Name : CT053

                          Product Type : Cell and Gene therapy

                          Upfront Cash : $29.6 million

                          January 16, 2022

                          Lead Product(s) : Zevorcabtagene Autoleucel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : CARsgen Therapeutics

                          Deal Size : $181.3 million

                          Deal Type : Collaboration

                          blank